167 related articles for article (PubMed ID: 34662771)
1. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
Rosenberg AJ; Agrawal N; Pearson A; Gooi Z; Blair E; Cursio J; Juloori A; Ginat D; Howard A; Chin J; Kochanny S; Foster C; Cipriani N; Lingen M; Izumchenko E; Seiwert TY; Haraf D; Vokes EE
Oral Oncol; 2021 Nov; 122():105566. PubMed ID: 34662771
[TBL] [Abstract][Full Text] [Related]
2. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
[TBL] [Abstract][Full Text] [Related]
3. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
Rosenberg AJ; Izumchenko E; Pearson A; Gooi Z; Blair E; Karrison T; Juloori A; Ginat D; Cipriani N; Lingen M; Sloane H; Edelstein DL; Keyser K; Fredebohm J; Holtrup F; Jones FS; Haraf D; Agrawal N; Vokes EE
BMC Cancer; 2022 Jan; 22(1):17. PubMed ID: 34980038
[TBL] [Abstract][Full Text] [Related]
4. Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes.
Foster CC; Seiwert TY; MacCracken E; Blair EA; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Gooi Z; Spiotto MT; Vokes EE; Haraf DJ
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):662-671. PubMed ID: 32311416
[TBL] [Abstract][Full Text] [Related]
5. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
O'Sullivan B; Huang SH; Siu LL; Waldron J; Zhao H; Perez-Ordonez B; Weinreb I; Kim J; Ringash J; Bayley A; Dawson LA; Hope A; Cho J; Irish J; Gilbert R; Gullane P; Hui A; Liu FF; Chen E; Xu W
J Clin Oncol; 2013 Feb; 31(5):543-50. PubMed ID: 23295795
[TBL] [Abstract][Full Text] [Related]
6. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
Patel RR; Ludmir EB; Augustyn A; Zaorsky NG; Lehrer EJ; Ryali R; Trifiletti DM; Adeberg S; Amini A; Verma V
Oral Oncol; 2020 Apr; 103():104608. PubMed ID: 32163853
[TBL] [Abstract][Full Text] [Related]
7. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
[TBL] [Abstract][Full Text] [Related]
8. Treatment de-escalation for HPV+ oropharyngeal cancer: A systematic review and meta-analysis.
Petrelli F; Luciani A; Ghidini A; Cherri S; Gamba P; Maddalo M; Bossi P; Zaniboni A
Head Neck; 2022 May; 44(5):1255-1266. PubMed ID: 35238114
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy.
Tsai CJ; McBride SM; Riaz N; Kang JJ; Spielsinger DJ; Waldenberg T; Gelblum D; Yu Y; Chen LC; Zakeri K; Wong RJ; Dunn L; Pfister DG; Sherman EJ; Lee NY
JAMA Oncol; 2022 Mar; 8(3):364-372. PubMed ID: 35050342
[TBL] [Abstract][Full Text] [Related]
10. Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
Waddle MR; Ma DJ; Visscher SL; Borah BJ; May JM; Price KA; Moore EJ; Patel SH; Hinni ML; Chintakuntlawar AV; Garcia JJ; Graner DE; Neben-Wittich MA; Garces YI; Hallemeier CL; Price DL; Kasperbauer JL; Janus JR; Foote RL; Miller RC
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):396-402. PubMed ID: 33359567
[TBL] [Abstract][Full Text] [Related]
11. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
12. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.
Lee NY; Sherman EJ; Schöder H; Wray R; Boyle JO; Singh B; Grkovski M; Paudyal R; Cunningham L; Zhang Z; Hatzoglou V; Katabi N; Diplas BH; Han J; Imber BS; Pham K; Yu Y; Zakeri K; McBride SM; Kang JJ; Tsai CJ; Chen LC; Gelblum DY; Shah JP; Ganly I; Cohen MA; Cracchiolo JR; Morris LGT; Dunn LA; Michel LS; Fetten JV; Kripani A; Pfister DG; Ho AL; Shukla-Dave A; Humm JL; Powell SN; Li BT; Reis-Filho JS; Diaz LA; Wong RJ; Riaz N
J Clin Oncol; 2024 Mar; 42(8):940-950. PubMed ID: 38241600
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
15. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.
Marur S; Li S; Cmelak AJ; Gillison ML; Zhao WJ; Ferris RL; Westra WH; Gilbert J; Bauman JE; Wagner LI; Trevarthen DR; Balkrishna J; Murphy BA; Agrawal N; Colevas AD; Chung CH; Burtness B
J Clin Oncol; 2017 Feb; 35(5):490-497. PubMed ID: 28029303
[TBL] [Abstract][Full Text] [Related]
16. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.
Huang SH; Xu W; Waldron J; Siu L; Shen X; Tong L; Ringash J; Bayley A; Kim J; Hope A; Cho J; Giuliani M; Hansen A; Irish J; Gilbert R; Gullane P; Perez-Ordonez B; Weinreb I; Liu FF; O'Sullivan B
J Clin Oncol; 2015 Mar; 33(8):836-45. PubMed ID: 25667292
[TBL] [Abstract][Full Text] [Related]
17. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
Petar S; Marko S; Ivica L
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4599-4603. PubMed ID: 33599841
[TBL] [Abstract][Full Text] [Related]
18. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.
Nichols AC; Lang P; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Fung K; de Almeida JR; Bayley A; Goldstein DP; Eskander A; Husain Z; Bahig H; Christopoulous A; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Mendez A; Winquist E; Read N; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Corsten M; Rajaraman M; Johnson-Obaseki S; Eapen L; Odell M; Chandarana S; Banerjee R; Dort J; Matthews TW; Hart R; Kerr P; Dowthwaite S; Gupta M; Zhang H; Wright J; Parker C; Wehrli B; Kwan K; Theurer J; Palma DA
BMC Cancer; 2020 Feb; 20(1):125. PubMed ID: 32059705
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
Gabani P; Lin AJ; Barnes J; Oppelt P; Adkins DR; Rich JT; Zevallos JP; Daly MD; Gay HA; Thorstad WL
Radiother Oncol; 2019 May; 134():81-88. PubMed ID: 31005228
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.
Lorch JH; Hanna GJ; Posner MR; O'Neill A; Thotakura VL; Limaye SA; Rabinowits G; Sher DJ; Tishler RB; Haddad RI
Head Neck; 2016 Apr; 38 Suppl 1():E1618-24. PubMed ID: 26614576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
